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Introduction: The use of novel designer drugs has increased worldwide over the
years. Etizolam is a designer benzodiazepine (BZD) that has raised concern because
of its growing non-medical use, liability to tolerance and dependence, and related
harms. Studies exploring the abuse liability and cognitive effects of etizolam outside the
therapeutic doses are lacking.
Aims: To explore the abuse liability of etizolam and the characteristics of patients affected
by etizolam high-dose dependence in a nationwide tertiary referral addiction unit. To
document the cognitive changes to etizolam high-dose use.
Design and Methods: Sociodemographic and clinical data on subjects with etizolam
high-dose use were retrospectively collected from a database of 1,293 patients
consecutively admitted to the Addiction Medicine Unit, Verona University Hospital,
Italy for detoxification from high-dose BZDs or Z-drugs dependence. Thorough
neuropsychological testing explored the cognitive side effects of high-dose etizolam use.
Results: We found eleven etizolam high-dose users, of which eight used etizolam only,
and three used etizolam with other BZDs/zolpidem. All the patients were prescribed
etizolam for medical reasons, i.e., anxiety and/or insomnia. Neuropsychological
evaluation showed deficits of working memory, visuospatial memory and executive
function in a 27-year-old woman who used etizolam 15 mg daily.
Discussion: Our findings suggest that abuse and dependence liability of etizolam should
be considered a public health and social problem. They offer preliminary evidence on the
cognitive side effects of etizolam high-dose use.
Conclusions: This report offers new information on the potential harms of etizolam in
patients who are prescribed this drug for medical reasons.
Keywords: benzodiazepine, BZD, cognition, dependence, etizolam, substance use disorder (SUD),
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INTRODUCTION
Benzodiazepines (BDZs) are gamma-amino-butyric acid type
A (GABA-A) receptor positive allosteric modulators widely
prescribed for anxiety, insomnia and other conditions (1).
The increasing use of novel designer BZD derivatives has been
recently reported in countries, where these chemical compounds
do not have marketing authorization as medicinal products (2).
Etizolam is a short-acting (half-life 5–7 h) thienodiazepine
designer BZD with high affinity for the GABA-A receptor and
anxiolytic and sedative properties (3). Etizolam is currently
approved for therapeutic use and marketed in three countries,
namely India, Italy and Japan, but available from the Internet for
research purposes worldwide (4). The few available comparative
studies reported that etizolam may induce less tolerance than
lorazepam and may have lesser sedative effects than alprazolam
and diazepam (4). The lower allosteric potency at the α1 subunit
of the GABA-A receptor has been proposed as one reason for the
reduced liability of etizolam to tolerance and dependence (5).
A consistent increase in the non-medical use and the illicit
drug market of etizolam has been reported since 2014, being this
drug implicated in several deaths in Scotland, United Kingdom,
and to a lesser extent in the United States and Sweden (4, 6). A
recent review concluded that few harms are documented with
the therapeutic use of etizolam, being predominantly related to
its non-medical use in illicitly manufactured pills and in the
context of mixed-drug toxicity, in particular in combination
with opioids (7). The World Health Organization Expert
Committee on Drug Dependence (WHO-ECDD) considered
etizolam abuse or dependence liability as an effectively public
health and social problem (4). Some questions on etizolam
side-effects profile are still unanswered. Evidence on etizolam
safety is based on preclinical studies and case reports. Common
adverse effects of etizolam include drowsiness, sedation and
slurred speech, but this drug is considered generally well-
tolerated in terms of cognitive side effects (4). The auditory
P300 was found to be prolonged with etizolam, but this
slowed brain response showed habituation, while attention and
memory appeared to be unaffected by etizolam (8). Therapeutic
etizolam doses (0.25–1mg) had no effect on cognition in
patients with anxiety (9) and on psychomotor performance and
vigilance (10). Cognitive effects to higher doses of etizolam are
still unexplored.
High-dose dependence of BZDs or related Z-drugs
(e.g., zolpidem, zopiclone, eszopiclone, zaleplon), i.e.,
daily intake ≥5 times the recommended maximum daily
dosage (1) is an emerging substance use disorder estimated
to affect 0.16% of the adult population in Switzerland
(11), associated to poor quality of life (12), and cognitive
dysfunction (13). Data on etizolam high-dose dependence
are lacking.
This report is aimed to (a) explore the liability of
etizolam to abuse and the characteristics of patients affected
by etizolam high-dose dependence in a nationwide tertiary
referral addiction unit; (b) document the cognitive changes
to etizolam in a high-dose user who underwent thorough
neuropsychological evaluation.
METHODS
Subjects with high-dose etizolam were retrospectively collected
from a database of 1,293 patients (650 men, 643 women)
aged >18 years and admitted (January 2003–December 2019)
to the Addiction Medicine Unit, Verona University Hospital,
Italy, a nationwide tertiary referral center for detoxification
from high-dose BZD/Z-drug dependence with slow flumazenil
infusion (14).
High-dose BZD/Z-drug dependence was defined according
to DSM-IV-TR criteria (15) with use lasting >6 months,
daily dosage exceeding at least 5 times the recommended
maximum intake (i.e.,>50mg of daily diazepam dose equivalent,
DDDE), otherwise problematic use of BZD/Z-drug, such as
mixing different molecules, escalating dosage, obtaining them
by illegal means, and using them to enhance the effect of other
substances (14).
We collected socio-demographic and clinical variables of the
patients. The dosage of BZD/Z-drugs was based on self-report.
DDDE (mg) was calculated according to conversion tables (14).









Marital status (single/engaged or married) 6/5
Clinical variables
Etizolam daily dosage 27.3 ± 29.3; 15; 5–100
Etizolam formulation (tablet/drops/both) 3/7/1
Concomitant abuse of other BZD/Z-drugs
(yes/no)
3/8
DDDE (mg)a 272.7 ± 263.5; 150; 70–1,000
BZD/Z-drug use duration (mos)a 36.6 ± 26.0; 24; 10–84
Age of first BZD/Z-drug intakea 24.6 ± 8.3; 21; 14–37
Reason for prescription (anxiety/sleep
disorders/both)
5/1/5






Psychiatric disorders (yes/no) 9/2
Anxiety disorders (yes/no) 6/5
Major depression (yes/no) 4/7
Other psychoses (yes/no) 1/10
Personality disorders (yes/no) 2/9
aMean ± SD; median; range. BZD, benzodiazepine; DDDE, daily diazepam dose
equivalent (sum of DDDEs for all BZDs and Z drugs in case of concomitant abuse of
other BZD/Z-drugs); Mos, months.
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FIGURE 1 | Results of the neuropsychological evaluation from one patient (woman, age 27 years, education 8 years) who took etizolam 15mg daily.
Neuropsychological findings are reported as Z-scores with negative values indicating worse performance and positive values indicating better performance than the
average value of the normal population. Abnormal values are worse than mean−1 SD; i.e., Z-scores <-1 indicate abnormal values. Shaded area indicates normal
range of values.
The diagnosis of psychiatric disorders was based on screening
tests, diagnostic interviews, and previous psychiatric assessments
or evaluations, when available.
Neuropsychological evaluation explored verbal memory,
working memory, visuospatial memory, attention and executive
function. Verbal memory was assessed by means of the Italian
versions of the Verbal Paired Association (VPA) (16) and
the Digit Span Forward Test (DSFT) (17). Working memory
was evaluated with the Digit Span Backward Test (DSBT)
(17) and Paced Auditory Serial Addition Test (PASAT-3) (18).
Visuospatial memory was explored with the 10/36 Spatial Recall
Test (SPART) (18). Attention was measured with the Trail
Making Test Part A (TMT-A) and the Symbol Digit Modalities
Test (SDMT) (18). Executive function was evaluated by means
of Trail Making Test Part B (TMT-B) (18) and the Stroop test
(19). Results were standardized as Z-scores. Cognitive testing was
performed 1 month before detoxification treatment.
All patients underwent a detoxification protocol with slow
subcutaneous flumazenil infusion (40.5 µg/h for 24 h/day for 7
days) with a prophylactic antiepileptic treatment (14).
The study was conducted according to the Declaration of
Helsinki and approved by the ethics committee of the Verona
University Hospital. All the patients gave written informed
consent to the study.
RESULTS
Among the patients admitted from January 2003 to December
2019, we found 11 patients (4 men, 7 women) who used high-
dose etizolam either as the only BZD (8 patients) or with other
BZDs or Z-drugs (3 patients; bromazepam: 1; lorazepam and
zolpidem: 1, clonazepam and triazolam: 1). All the patients were
prescribed etizolam for medical use (anxiety: 5 patients; sleep
disorders: 1; both reasons: 5) and obtained the drug through a
prescription and a pharmacy. The number of patients was stable
across years (2003–2007: 2 patients; 2008–2011: 3; 2012–2015: 4;
2016–2019: 2). Sociodemographic and clinical features of patients
are reported in Table 1.
The remaining 1,282 patients used other BZD/Z-drugs high-
doses [for further details see (12, 13)].
One patient (woman, 27 years, education 8 years; 15mg of
etizolam daily) underwent neuropsychological evaluation that
showed working memory, visuospatial memory, and executive
function to be outside normal values (i.e., >1 SD worse than
normal controls; Figure 1). No medical conditions or other
substance use disorder that could have contributed to the
cognitive deficits were reported.
DISCUSSION
To the best of our knowledge, this is the first report of etizolam
high-dose dependence in 11 patients who received etizolam for
medical reasons (anxiety and/or sleep disorders). Our patients
received on average 27.3 ± 29.3mg etizolam daily, which is
nearly ten times the maximum recommended daily dosage (i.e.,
3mg), with one patient taking 100mg daily, i.e., >30 times the
maximum daily dosage. These findings support the conclusion of
the recent WHO-ECDD report that abuse/dependence liability
of etizolam should be considered as a public health and social
problem (4). They are also in keeping with individual users
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reports on forums like Bluelight.org (20) and Erowid.org (21)
that describe tolerance, craving and withdrawal to etizolam (7).
Etizolam high-dose users represented 0.9% of our whole
sample and did not increase during the nearly 20 years covered
by our large database, suggesting some concern, but stable figures
across time. The big size difference between etizolam and other
BZDs/Z-drugs high-dose users hampered a reasonable statistical
comparison. However, when compared to high-dose users of
lormetazepam, i.e., the most common BZD of high-dose use in
Italy (22), etizolam high-dose users appear to be more frequently
women, younger, more frequently employed, with lower DDDE,
shorter BZD/Z-drug use duration, smaller age of first BZD/Z-
drug intake and more frequent poly-drug use. These findings
suggest that some populations of patients might be more prone
to non-medical use and dependence of etizolam. In particular,
they confirm the risk of etizolam harms in patients with other
substance use disorders (4).
The small number of etizolam high-dose users in our large
sample is likely related to the number of prescriptions in the
general population. Etizolam does not stand among the ten most
prescribed BZD active principles in Italy, in that its defined daily
dose (DDD) in 2018 was <0.5/1,000, while that of the most
commonly ones ranged from 13.2 for lormetazepam to 0.7 for
flurazepam (23). The absence of data on etizolam prescription
in Italian population, however, hampers the estimation of the
conversion-rate from etizolam prescription to addiction.
Etizolam negatively influenced most of the cognitive domains
in the patient who underwent neuropsychological testing, in
particular working memory, visuospatial memory, and executive
function, some of them being <2 SDs worse than normal values.
This finding, despite being preliminary since stemming from a
single patient, extends the notion that high doses of BZDs have
an impact on cognition, even in younger patients (13, 24). BZDs
cognitive side effects have been suggested to be related to the
function of the GABA-A receptor α1 (responsible for anterograde
amnesia) and the α5 subunits, which are involved in cognition,
learning and memory (25). Based on animal studies showing
etizolam lower affinity for the GABA-A receptor α1 subunit than
the α5 one (5), we speculate that the cognitive effects of etizolam
high-dose intake in our patient might be mainly mediated by the
interaction with the α5 subunit.
The strengths of this study are that it represents the first
series of etizolam high-dose users, and offers new information
on the harms of this BZD derivative from a nationwide referral
center in one of the few countries where it is marketed. The
limitations are the retrospective design, the absence of systematic
quantitative BZD measures to verify self-reported data, and
neuropsychological data from a single patient that suggest
caution in generalizing our findings on cognitive side effects
of etizolam.
In conclusion, a small number of patients who use etizolam
for therapeutic reasons appear to transition to high-dose use
requiring specialist care. This report offers new information on
the potential harms related to etizolam and extends them to
patients who are prescribed this drug for medical reasons. Future
studies should confirm our findings in larger populations and in
other countries where etizolam is marketed.
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